8/24/2010

The FDA denied EpiCept's application to market Ceplene, a drug candidate for acute myeloid leukemia, because of concerns about the treatment's effectiveness. The agency recommended an additional clinical study to verify Ceplene's efficacy when used in combination with anti-cancer agent interleukin-2.

Related Summaries